How a Split FDA Advisory Panel Voted Six of Seven Peptides Onto the 503A Compounding List Over Its Own Scientists, Rejecting Only Emideltide, and What That Actually Changes for the Market

FDA’s career scientists recommended against all 7 peptides up for review at last week’s advisory committee meeting. The committee voted yes on 6. Here is what that split actually tells you.

The 8 yes votes on Day 1 belonged entirely to 8 temporary members added to the committee shortly before the meeting. All 6 pre-existing members voted no. That is not …